Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Stomach Neoplasms 2Pancreatic Neoplasms 2Small Cell Lung Carcinoma 1Pancreatic cancer, adult 1Osteosarcoma 1Neoplasms 1NSCLC 1Locally Advanced Pancreatic Cancer 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Advanced Pancreatic Cancer 1Adenoma, Islet Cell 1

Interventions

Exercise 9Standard of Care 5trametinib 3tislelizumab 3Radiotherapy 3Radiosurgery 3Palliative Care 3Paclitaxel 3Gemcitabine 3Carboplatin 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2cemiplimab 2Therapeutics 2Surveys and Questionnaires 2Resistance Training 2Oxaliplatin 2Maintenance 2Immune Checkpoint Inhibitors 2Drug Therapy 2Cisplatin 2Anastrozole 2vedolizumab 1toripalimab 1surufatinib 1sparsentan 1sintilimab 1semaglutide 1posaconazole 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Neoplasms × surufatinib × Clear all
NCT07279532 2025-12-12

Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
35 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡